RIAdvisorRatings.com · An Investor Education Series
Every stock price contains a hidden set of assumptions about the future. This tutorial teaches you to read those assumptions the way a risk analyst does – and to tell, objectively, whether the stocks you own are priced for safety or priced for disappointment.
Most investors judge a stock by its story: a great product, a famous brand, a chart that has gone up. None of that tells you whether you are likely to make money from here. What determines that is the price you pay relative to what the business actually produces – its sales, its earnings, its cash flow, and the net worth behind it that demonstrably inures to the benefit of the shareholders.
We are going to walk you through four simple ratios, show you what separates a low‑risk ratio from a high‑risk one, and then look at 50 real companies from the S&P 500 to see what happened to investors who ignored them. By the end you will be able to look at your own portfolio and ask the one question that matters: what would have to come true for me to make money?
The core idea. When you buy a stock, the benefit you receive in the future is based on, and measured relative to, what the business has already done. A high price relative to today's sales and profits only makes sense if you believe the future will be significantly bigger than the present. The higher the difference between its current value and its current price, the more the future has to deliver, and the more room there is to be wrong.
A ratio simply compares the company's price (its market capitalization – the total value of all its shares) to something the business produces. Here are the four we use, in plain language.
How many years of the company's total sales you are paying for. A P/S of 3 means you are paying three dollars for every one dollar of annual sales. The higher the P/S ratio, the higher the hurdle rate there is for making a profit.
How many years of current profit you are paying for. A P/E of 35 means that, at today's earnings, it would take 35 years of profits to earn back your purchase price. The higher the P/E, the faster profits must grow to justify it.
How many years of actual cash the business generates you are paying for. Free cash flow is the money left after the company pays to keep itself running and growing. It is harder to disguise than reported earnings, which makes it one of the hardest measures to manipulate.
How much you are paying above the company's real, physical net worth – its assets minus its debts, excluding accounting intangibles like goodwill. A very high P/TE (or a negative one, meaning debts exceed tangible assets) tells you the price rests entirely on expectations, with little hard asset value underneath.
You don't need to memorize thresholds. The clearest reference point is what the whole S&P 500 has typically traded at over the last 25 years. Pay a lot more than that, and you are counting on this company being an exception.
| Ratio | The market's 25‑year typical | What paying well above it means |
|---|---|---|
| Price / Sales | about 1.6× | You are paying a premium the business has to grow into. |
| Price / Earnings | about 18× | More years of today's profit than the market usually asks. |
The further above the market's normal you pay, the more the future has to go right just for you to break even. The next step shows exactly what that means in dollars.
Here is the heart of it. A high price is not automatically wrong, but it is a promise about the future. Let's make that promise visible. The calculator below shows your five‑year return under two futures: one where the price‑to‑sales ratio never changes, and one where it reverts toward what the market normally pays.
The marker at 1.6× is the S&P 500's typical price‑to‑sales ratio over the last 25 years.
Variation 1 – if P/S stays the same
–
Your return equals the sales growth, compounded. This assumes the market keeps paying today's rich multiple five years from now.
Variation 2 – if P/S reverts to the future ratio you set
–
Your return once the multiple normalizes toward what you set above (default: the market's 1.6× median).
–
There is no science that can pinpoint a company's exact price five years from now. But data science can tell you two things we hold with very high confidence:
1. The vast majority of companies will one day trade at roughly the market's median price‑to‑sales ratio – about 1.6×. When that happens, you can see exactly what your profit, or loss, will be. Set the future ratio to 1.6× above and read Variation 2.
2. The gap between the market's median ratio and its lower‑quartile ratio is enormous. A reasonable person, and certainly a fiduciary, is obligated to estimate what would happen to the price if the ratio reverted not just to the median but to the lower quartile of the market's history. We cannot pinpoint the future ratio, but for a given company we can give you a high‑probability range of where it is likely to land, based on the nature of that specific business, and we have the data to do exactly that.
The economy grows about 2–4% a year. A typical large company cannot sell significantly more than that for long, call it 4–6% with some foreign exposure. A few exceptional businesses grow 15–20% for a while, but that is rare, and it almost never continues once a company is already enormous. So when a price requires high sales growth every year for five years just to hold its value, you are betting on the exception, not the rule.
Ask yourself: if I pay 3 or 4 times sales today, and the multiple later reverts toward the market's 1.6× median, what happens to my money even if sales grow nicely? What would a future buyer have to believe to keep paying today's rich price? If you cannot answer that question concretely, we're here to help.
Here is the lesson most investors never learn. The companies people like the most, and buy the most, tend to end up with the highest prices, the highest valuations, and the biggest gap between what the business is worth and what it costs. So the 50 companies we studied are not random losers. They are 50 companies investors had enormous confidence in.
How do we know they were confident? Because of what they were willing to pay. At their highs, this group commanded $3.69 for every dollar of sales, roughly $33 for every dollar of earnings, and $84 for every dollar of tangible net worth. You do not pay those prices for a company you doubt. Historically, companies that go on to rise have started out priced at much less than half of those levels.
We took the S&P 500 and identified the 50 companies with the largest peak‑to‑trough price declines from June 30, 2021 to June 30, 2026. Here is what the market paid for all 50 at their highs, and what they were worth at their lows.
Combined value at the highs
$4.17 trillion
Combined value at the lows
$0.94 trillion
That is a 78% loss of market value. Over the same period, these companies' sales actually grew 18%. The businesses kept selling. What collapsed was the price investors were willing to pay for each dollar those businesses produced, falling to much less than half of where it started, which means the price was probably overvalued by a factor of around four to begin with.
And that fall was, in aggregate, predictable. Not stock by stock, but the way a public‑health statistic is predictable. Ask a room of smokers their odds of cancer and most say "not me," yet we know lung cancer strikes roughly one in ten. In the same way, not every richly‑priced company falls, and we can point to some that rose. But the vast majority fall, and this study points exactly to that.
| Measure | At the high | At the low | Reduction |
|---|---|---|---|
| Price / Sales | 3.69× | 0.70× | −81% |
| Price / Earnings | 34.8× | 17.6× | −49% |
| Price / Tangible Equity | 83.6× | 34.1× | −59% |
| Price / Free Cash Flow | 31.7× | 10.6× | −67% |
The story is written in this table. Investors started out paying rich multiples. Those multiples fell back toward normal. That fall, not any business failure, is where the 78% went.
What made these purchases weak was not the businesses themselves but the fact that, at the price paid, they were not backed by solid assets. That shows up in one number: the price relative to the company's tangible net worth was extremely high. Note the direction: the price was high, not the net worth. Investors were looking at healthy profit margins and fast sales growth and assuming both would continue forever. They did not, and they will not, which is almost always the case.
The reason is simple. When you buy a company at three to four times sales, thirty‑five times earnings, and eighty‑plus times tangible equity, the price you are paying is already far above what the business is worth. Buying a company at those ratios and having it go up is close to impossible, on the order of one or two out of a hundred. It is far more probable that you lose a great deal of money. This is not opinion. As data scientists, we work from math, not stories, and the math on those ratios is unforgiving.
The bottom line. You will lose money when the net present value of the company you buy is lower than its market cap. That was the case for effectively every one of these 50 companies, and it is the case for the vast majority of companies on average. Buying at a price above intrinsic value is dangerous, a point the financial researcher Hendrik Bessembinder has made abundantly clear in his work on how few stocks account for the market's gains.
Sort the table below. Notice the pattern: the companies that began with the highest ratios were, over and over, the ones with the least value backing their price. The final column shows each company's intrinsic value as a percentage of its price at the high (explained in Step 5). Anything under 100% means investors were paying more than the business was worth. Click any column heading to sort.
| Company | P/S | P/E | P/FCF | P/TE | Intrinsic value* (% of price) |
|---|
*Estimate based on ERS's Fiduciary Prism™. Call us for more details.
Everything so far has taught you to read risk. This final step teaches you to avoid it. There is one disciplined test that separates a sound purchase from a hopeful one:
The rule: only buy a company when its intrinsic value – what the business is worth – is greater than the price you are being asked to pay. In one line: intrinsic value must exceed market capitalization.
Here is the part most investors get wrong. A company is worth two things added together, and you have to count both:
1. What it's worth right now – the hard-asset floor. If the business stopped growing tomorrow, what could you recover from what it already owns? We add up its cash, its inventory and receivables, its property and equipment, and its investments – each counted conservatively at what it would realistically fetch – and then we subtract every dollar it owes. What's left is the floor. For a company with heavy debt, this floor can be negative: the company owes more than its assets could recover. That is a red flag you can see before you ever think about the future.
2. What its future cash is worth today – the discounted cash flow. On top of that floor, we add the value of the cash the business will realistically generate in the years ahead, translated back into today's dollars – because a dollar received years from now is worth less than a dollar today.
Add the floor and the future together and you have the company's intrinsic value. Compare it to the price. If the price is higher than intrinsic value, you are paying for a future that has to exceed reasonable expectations – that is the definition of high risk.
The discipline is in the assumptions. Rather than assume today's growth lasts forever, the calculation deliberately leans conservative at every step:
This is the same engine behind the Fiduciary Prism™. If future cash generation is zero or negative, intrinsic value rests entirely on the hard-asset floor – exactly as a careful buyer would treat it.
For each company we calculated intrinsic value on the very day it hit its high, and compared it to what investors were paying. The result is stark:
Paying more than the company was worth
47 of 50
At their highs, intrinsic value was below the market price for 47 of the 50.
The typical price paid
$4.17
for every $1 of intrinsic value. The median company's value was just 24% of its price.
Only three of the fifty – and two others had a negative intrinsic value, meaning their debts overwhelmed both their assets and their cash generation. Line the companies up by this one measure and it tells you almost everything the four ratios told you, in a single number: the richly-priced names were worth pennies on the dollar of what investors paid.
And here is the encouraging half. Run the same test at the lows, after prices fell, and the picture flips: intrinsic value rose to a median of 56% of price, and 15 of the 50 now passed the test outright. The businesses hadn't changed much – the price had. That is the whole point of the discipline: it doesn't tell you a company is bad, it tells you when the price is wrong, and when a fallen price has finally become fair.
You now have the tools a risk analyst uses. Pull up the stocks you own and ask three questions of each one:
1. Where do my ratios sit? Are they in the lower‑risk bands, or the high‑risk ones?
2. What does the price silently require? How fast would sales and profits have to grow for me to make money – and is that realistic for a company this size?
3. Does intrinsic value exceed the price? Counting both what the business is worth today and its future cash, is it worth more than I am paying – or am I paying for a future that has to go perfectly?
If your portfolio is concentrated in companies with high‑risk ratios and prices above their intrinsic value, then it looks like the portfolio of 50 you just studied. And portfolios that look alike tend to behave alike.
Equity Risk Sciences produces independent risk ratings on thousands of stocks – the same disciplined analysis you just walked through, done for you, name by name.
See the ratings at ERS.ai